To optimize the yields, viral-based influenza vaccine manufacturers generally use candidate vaccine viruses (CVVs), which are generated by reassortment of the representative HA and NA antigens with a non-pathogenic, high-growth influenza genome backbone such as the one from the A/PR8/1934 (PR8) strain [14]. This evidence concerns the gene XK and influenza.